Skip to main content

Table 2 Patient-based characteristics

From: [68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study

Pat

Age

T1

T2

GSC

ADT

ADT

(days)

CTx

Initial PSA

(ng/ml)

PSA after ADT

∑ PSMA-TV at T2 in % of T1

∑ TL-PSMA at T2 in % of T1

(ng/ml)

[% of T1]

1

60

MR

CT2

4 + 3

B

219

6 Cycles

80

0.41

0.5

4.50

5.89

2

64

CT1

CT2

5 + 4

L

289

6 Cycles

5.9

0.15

2.5

2.80

4.34

3

59

CT1

CT1

5 + 4

Max

279

6 Cycles

2.49

0.27

10.8

12.62

8.95

4

74

CT1

CT2

4 + 4

Max

149

X

29.14

0.69

2.4

9.65

15.78

5

57

MR

CT2

4 + 3

Max

218

X

45.4

0.71

1.6

38.12

94.63

6

74

MR

MR

4 + 4

Max

61

X

57.5

1.42

2.5

35.12

28.80

7

73

MR

MR

4 + 5

Max

98

X

14.06

0.1

0.7

16.71

11.42

8

74

CT1

MR

4 + 3

Max

115

X

25.8

0.05a

0.2

23.35

2.94

9

79

MR

CT1

4 + 5

Max

156

X

42.06

1.9

4.5

44.38

33.59

10

79

MR

CT1

4 + 4

B

116

X

17.97

1.52

8.5

53.13

50.02

11

76

CT1

CT1

4 + 3

Max

118

X

100.4

1.93

1.9

39.57

9.29

12

65

MR

CT1

4 + 5

Max

155

X

91.5

0.09

0.1

0.00

0.00

13

59

CT1

CT1

4 + 4

Max

81

X

32.9

3.08

9.4

206.69

267.85

14

66

CT1

CT1

4 + 4

Max

168

6 Cycles

107

0.21

0.2

42.53

6.50

15

74

CT1

CT1

4 + 4

Max

174

X

16.17

0.93

5.8

16.96

2.73

16

80

CT1

CT1

4 + 5

Max

253

X

12.07

0.45

3.7

63.50

30.34

17

66

CT1

CT1

3 + 4

Max

205

4 Cycles

31.5

0.05

0.2

0.00

0.00

18

70

CT1

CT1

4 + 4

Max

109

X

21

4.91

23.4

59.97

51.12

19

81

CT2

CT2

4 + 3

Max

102

X

26.13

3.53

13.5

45.78

40.14

20

57

CT2

MR

5 + 4

Max

134

X

36.2

1.34

3.7

52.09

6.18

21

59

CT2

CT2

4 + 3

Max

158

X

23.5

2.26

9.6

93.89

90.35

  1. GSC, Gleason score; ADT, androgen deprivation therapy; CTx, chemotherapy/in all cases Docetaxel; B, bicalutamide 150 mg/d; L, leuprorelin 11.25 mg/3 months; Max, maximal androgen blockade (leuprorelin 11.25 mg/3 months + bicalutamide 50 mg/d)
  2. Changes in PSA and PSMA-derived tumor volumes (primary tumor, lymph node metastases and bone metastases), PSMA-TV and TL-PSMA. Patients with a T2 PSA > 1 ng are in italics
  3. aPatient 8 underwent TUR-P in the meantime